美国哮喘生物制剂使用的趋势和差异。
Trends and Disparities in Asthma Biologic Use in the United States.
机构信息
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minn.
Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.
出版信息
J Allergy Clin Immunol Pract. 2020 Feb;8(2):549-554.e1. doi: 10.1016/j.jaip.2019.08.024. Epub 2019 Aug 28.
BACKGROUND
From 2003 to 2015, only 1 biologic was approved for the treatment of moderate to severe asthma in the United States. Since 2015, 4 new asthma biologics were approved by the US Food and Drug Administration.
OBJECTIVE
To describe trends and disparities of asthma biologic use in the United States from 2003 to 2018.
METHODS
We conducted a retrospective analysis using a cohort developed from the OptumLabs Data Warehouse. Prevalent and incident asthma biologic users were identified, and characteristics of users and nonusers were analyzed using regression analysis. Clinician prescribing behavior was described.
RESULTS
Use of biologic medications remains uncommon among individuals with asthma, with prevalence peaking in 2006 at 3 in 1000 individuals with asthma. Several factors are associated with a higher likelihood of asthma biologic use: middle age, higher income, commercial insurance, and access to a specialist. Most clinicians (65%) in the cohort prescribed only 1 biologic.
CONCLUSIONS
We report low overall use of asthma biologics and evidence of disparities in access to asthma biologics.
背景
从 2003 年到 2015 年，美国仅批准了一种生物制剂用于治疗中重度哮喘。自 2015 年以来，美国食品和药物管理局批准了 4 种新的哮喘生物制剂。
目的
描述 2003 年至 2018 年美国哮喘生物制剂使用的趋势和差异。
方法
我们使用来自 OptumLabs 数据仓库开发的队列进行了回顾性分析。确定了现患和新发哮喘生物制剂使用者，并使用回归分析分析了使用者和非使用者的特征。描述了临床医生的处方行为。
结果
在哮喘患者中，生物制剂的使用仍然不常见，哮喘患者的患病率在 2006 年达到峰值，为每 1000 人中有 3 人。一些因素与更高的哮喘生物制剂使用可能性相关：中年、更高的收入、商业保险和获得专家的机会。该队列中的大多数临床医生（65%）仅开了一种生物制剂。
结论
我们报告了哮喘生物制剂总体使用率较低，并发现哮喘生物制剂的使用存在差异。
Zotero 插件